Bank of New York Mellon Corp Buys New Stake in Ingevity Corporation $NGVT

Key Points

• Bank of New York Mellon acquired 214,739 Ingevity shares worth approximately $16.0 million, joining other institutional investors; institutions now own 91.59% of the company.
• Ingevity insiders sold 17,801 shares worth $1.35 million over the past 90 days, including sales by the CEO and a senior vice president under a Rule 10b5-1 plan.
• The stock carries a consensus “Hold” rating with an $80 average price target. Ingevity recently beat quarterly EPS estimates, reporting $1.74 versus the $1.33 consensus, and issued fiscal 2026 EPS guidance of $5.00–$5.45.

Bank of New York Mellon Corp acquired a new position in Ingevity Corporation (NYSE:NGVT - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 214,739 shares of the company's stock, valued at approximately $16,035,000. Bank of New York Mellon Corp owned about 0.62% of Ingevity at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Global Retirement Partners LLC acquired a new stake in shares of Ingevity in the 4th quarter worth $27,000. Meeder Asset Management Inc. purchased a new stake in Ingevity in the fourth quarter valued at about $33,000. Geneos Wealth Management Inc. raised its stake in Ingevity by 85.8% in the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company's stock valued at $36,000 after buying an additional 387 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Ingevity in the second quarter worth about $46,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Ingevity during the fourth quarter worth about $47,000. Institutional investors own 91.59% of the company's stock.

Insider Buying and Selling

In other news, CEO David H. Li sold 5,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $75.83, for a total value of $379,150.00. Following the completion of the transaction, the chief executive officer directly owned 120,636 shares in the company, valued at $9,147,827.88. This trade represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ryan C. Fisher sold 2,709 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $73.72, for a total value of $199,707.48. Following the sale, the senior vice president directly owned 15,722 shares in the company, valued at approximately $1,159,025.84. The trade was a 14.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 17,801 shares of company stock worth $1,347,481. Corporate insiders own 0.88% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Friday, July 31st. Wall Street Zen downgraded shares of Ingevity from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 1st. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $80.00.

Ingevity Stock Performance

NYSE NGVT opened at $69.48 on Tuesday. The business's 50-day moving average price is $73.47 and its 200 day moving average price is $71.76. The company has a current ratio of 1.61, a quick ratio of 1.15 and a debt-to-equity ratio of 22.52. Ingevity Corporation has a twelve month low of $45.85 and a twelve month high of $79.29. The company has a market capitalization of $2.39 billion, a PE ratio of 47.27 and a beta of 1.16.

Ingevity (NYSE:NGVT - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.33 by $0.41. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.The firm had revenue of $314.10 million during the quarter, compared to the consensus estimate of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, research analysts predict that Ingevity Corporation will post 5.4 earnings per share for the current year.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

Want to see what other hedge funds are holding NGVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ingevity Corporation (NYSE:NGVT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.